Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters

Semin Perinatol. 2005 Aug;29(4):252-7. doi: 10.1053/j.semperi.2005.05.004.

Abstract

Objective: To predict the screening performance for 17 policies currently in use or being considered for the near future.

Methods: Multivariate Gaussian modeling using parameters derived from published meta-analyses and new meta-analyses for gestation-specific nuchal translucency and between trimester correlations.

Results: For a 1% to 5% false-positive rate, first trimester screening achieved detection rates up to 16% to 25% higher than the best second trimester combination. Screening in both trimesters sequentially could yield an even greater increase in detection of 24% to 35%. The most efficient sequential policy was contingent screening, which has a high detection rate with only 15% of women needing second trimester tests.

Conclusion: Modeling with meta-analysis derived parameters provides a reliable guide for policy and favors a contingent screening policy. The widespread practice of calculating first and second trimester risks separately should be abandoned.

MeSH terms

  • Chorionic Gonadotropin / blood
  • Down Syndrome / blood
  • Down Syndrome / diagnosis*
  • Estriol / blood
  • Female
  • Fetal Diseases / blood
  • Fetal Diseases / diagnosis*
  • Fetus
  • Humans
  • Maternal Age
  • Meta-Analysis as Topic*
  • Models, Statistical*
  • Multivariate Analysis
  • Normal Distribution
  • Nuchal Translucency Measurement
  • Pregnancy
  • Pregnancy Trimester, First
  • Pregnancy Trimester, Second
  • Pregnancy-Associated Plasma Protein-A / metabolism
  • Prenatal Diagnosis / methods*
  • Prenatal Diagnosis / standards
  • alpha-Fetoproteins / metabolism

Substances

  • Chorionic Gonadotropin
  • alpha-Fetoproteins
  • Pregnancy-Associated Plasma Protein-A
  • Estriol